ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 130 filers reported holding ASCENDIS PHARMA A/S in Q3 2019. The put-call ratio across all filers is 0.17 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $280 | -99.9% | 2,995 | +69.1% | 0.03% | +86.7% |
| Q1 2022 | $208,000 | -56.6% | 1,771 | -50.2% | 0.02% | -69.4% |
| Q4 2021 | $479,000 | +116.7% | 3,558 | +111.5% | 0.05% | +133.3% |
| Q2 2021 | $221,000 | -19.9% | 1,682 | -5.9% | 0.02% | -55.3% |
| Q3 2020 | $276,000 | -56.3% | 1,787 | -67.4% | 0.05% | +27.0% |
| Q2 2019 | $631,000 | +173.2% | 5,483 | +179.2% | 0.04% | +184.6% |
| Q1 2019 | $231,000 | +1.8% | 1,964 | -43.5% | 0.01% | +8.3% |
| Q1 2018 | $227,000 | – | 3,478 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |